Lee Dilworth, MD
Cardiovascular Disease · Knoxville, TNNPI 1043209844
Payments from drug & device makers
What this record shows
This record is dominated by education: $390 of the $645 with a category attached, or 60.5%. Astellas Pharma US Inc accounts for 60.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $205 and has fallen 85.8% since, to $29 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in TN, where the typical reported total is $1,892.
Across 16 payments — averaging $40.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$390
- Boehringer Ingelheim$89
- Baxter Healthcare$60
- Amgen$50
- Daiichi Sankyo Inc.$29
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15
- plus $12 from 1 others
What the payments were for
- Food & beverage$25540%
- Education$39060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 5 | $390 |
| Boehringer Ingelheim | 1 | $89 |
| Baxter Healthcare | 3 | $60 |
| Amgen | 3 | $50 |
| Daiichi Sankyo Inc. | 2 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Bayer | 1 | $12 |
How this compares
$645 in reported general payments places this provider in the 30th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 230 | $239,537 |
| EntrestoSacubitril/Valsartan | 116 | $123,132 |
| XareltoRivaroxaban | 108 | $96,551 |
| Repatha SyringeEvolocumab | 13 | $7,153 |
| Ranolazine ErRanolazine | 42 | $3,088 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 171 | $3,016 |
| Rosuvastatin Calcium | 243 | $2,338 |
| Metoprolol Succinate | 173 | $2,279 |
| Potassium Chloride | 151 | $2,132 |
| Hydralazine Hcl | 188 | $1,983 |
| Nitroglycerin PatchNitroglycerin | 44 | $1,754 |
| Prasugrel Hcl | 26 | $1,614 |
| Bumetanide | 64 | $1,526 |
| Nitroglycerin | 149 | $1,496 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 41 | $1,233 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Knoxville
- Jeffrey JohnsonKnoxville$94K
- Neil BarryKnoxville$23K
- Joseph LiuKnoxville$22K
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Steven GubinMemphis$248K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- Selcuk TombulChattanooga$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.